Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Crinetics Pharmaceuticals (Nasdaq: CRNX) will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after market close.
Management will host a conference call and webcast the same day at 4:30 p.m. ET to discuss results and provide a business update. Dial-in numbers and an access code are provided for domestic and international participants, and a live webcast will be available and later archived on the company’s Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CRNX gained 0.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CRNX fell 3.22% while close biotech peers were mixed: IMVT +3.02%, KYMR +2.81%, APLS +1.85%, PTGX -0.28%, VKTX -0.63%, suggesting a stock-specific move rather than a sector-wide shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Inducement equity grants | Neutral | -1.9% | Disclosed stock options and RSUs granted to new non-executive employees. |
| Jan 06 | Equity offering priced | Negative | -4.6% | Underwritten public offering of 7,620,000 shares at $45.95 per share. |
| Jan 05 | Equity offering proposed | Neutral | +3.1% | Announced intent to raise $350.0M in an underwritten common stock offering. |
| Jan 05 | Clinical data update | Positive | +3.1% | Positive Phase 2 atumelnant data and early PALSONIFY U.S. net product revenue. |
| Jan 04 | Clinical update call | Neutral | +3.1% | Announced business update and topline Phase 2 atumelnant results webcast. |
Recent news, including clinical data and capital raises, generally saw share price moves in the same direction as the news tone, with no clear history of market overreaction.
Over the past few months, CRNX has reported several key events, including positive Phase 2 atumelnant data and early PALSONIFY launch metrics on Jan 5, 2026, and a follow-on equity offering priced on Jan 6, 2026. Inducement grants were disclosed on Jan 12, 2026. These updates combined clinical progress, commercialization ramp, and balance-sheet strengthening. Today’s earnings date announcement follows this sequence of operational and financing milestones, setting expectations for full Q4 and 2025 financial disclosure on Feb 26, 2026.
Market Pulse Summary
This announcement schedules the release of fourth quarter and full year 2025 results for February 26, 2026, with a conference call at 4:30 p.m. ET. It follows recent clinical data, PALSONIFY launch updates, and an equity offering that strengthened the balance sheet. Investors may focus on how reported revenue, cash levels, and operating expenses compare with prior disclosures and recent unaudited figures once the full results are presented.
AI-generated analysis. Not financial advice.
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, February 26 at 4:30 p.m. ET
| Domestic: | 1 833-470-1428 | |
| International: | 1 646-844-6383 | |
| Access Code: | 027322 | |
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When will Crinetics Pharmaceuticals (CRNX) report Q4 and full year 2025 results?
What time is the Crinetics (CRNX) earnings conference call on February 26, 2026?
How can investors join the Crinetics (CRNX) earnings call and webcast?
Will the Crinetics (CRNX) webcast be available after the call?
How early should participants connect to the Crinetics (CRNX) webcast on February 26, 2026?
